Gyre Therapeutics
GYRE
17 hedge funds and large institutions have $2.48M invested in Gyre Therapeutics in 2017 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 13 closing their positions.
348% more call options, than puts
Call options by funds: $1.51M | Put options by funds: $337K
16% more capital invested
Capital invested by funds: $2.15M → $2.48M (+$333K)
3.24% more ownership
Funds ownership: 0.24% → 3.49% (+3.2%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
37% less funds holding
Funds holding: 27 → 17 (-10)
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
62% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 13
Top Buyers
| 1 |
Renaissance Technologies
New York
|
+$312K |
| 2 |
Simplex Trading
Chicago,
Illinois
|
+$129K |
| 3 |
BlackRock
New York
|
+$73.6K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$65.9K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$32.6K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$58 | -1 | -50% |
|
27
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$58 | -1 | -50% |
|
GYRE Hedge Fund Activity: Q1 2017 in Review
17 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Gyre Therapeutics (GYRE) for Q1 2017, worth a combined $2.48M — up 16% from $2.15M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of GYRE and 5 opened new positions — a net loss of 8 holders — while 5 trimmed existing stakes and 2 added.
The largest buyer was Renaissance Technologies, adding an estimated $312K. The largest seller was Colorado Capital Management, exiting entirely with an estimated $50K sold.
- 17 institutional investors held Gyre Therapeutics (GYRE) as of Q1 2017, down from 27 in Q4 2016.
- Funds reported $2.48M of Gyre Therapeutics stock for Q1 2017, up 16% quarter-over-quarter.
- 5 funds opened new Gyre Therapeutics positions in Q1 2017 and 13 closed out, a net change of -8 holders.
- The largest Gyre Therapeutics buyer in Q1 2017 was Renaissance Technologies, an estimated $312K added.
- The largest Gyre Therapeutics seller in Q1 2017 was Colorado Capital Management, an estimated $50K sold.
Based on aggregated 13F filings for Q1 2017.